The knockdown of BDNF-AS or intervention with miR-125b-5p reduced these effects, suggesting that the miR-125b-5p/BDNF-AS ratio may serve as a biomarker and therapeutic target for AD treatment. Here, BDNF is linked to Alzheimer disease.